We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
-5.05%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.37B
AUM Growth
-$155M
Cap. Flow
-$860M
Cap. Flow %
-25.49%
Top 10 Hldgs %
37.46%
Holding
92
New
13
Increased
23
Reduced
14
Closed
19

Top Buys

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$85.8M
2
KROS icon
Keros Therapeutics
KROS
+$61.7M
3
LEGN icon
Legend Biotech
LEGN
+$59.5M
4
TMO icon
Thermo Fisher Scientific
TMO
+$49.3M
5
GERN icon
Geron
GERN
+$28M

Top Sells

Rank Stock Value
1
PEN icon
Penumbra
PEN
+$40.4M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$39M
3
ARVN icon
Arvinas
ARVN
+$31.6M
4
APLS
Apellis Pharmaceuticals
APLS
+$30.9M
5
DXCM icon
DexCom
DXCM
+$29.6M

Sector Composition

Rank Sector Weight
1 Healthcare 66.36%
2 Miscellaneous 33.64%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$15.7B
$123M 3.65%
901,790
-15,884
-2% -$1.96M
XENE icon
2
Xenon Pharmaceuticals
XENE
$5.81B
$114M 3.39%
2,913,964
+206,709
+8% +$8.55M
LEGN icon
3
Legend Biotech
LEGN
$3.87B
$96.9M 2.87%
2,977,951
+1,436,400
+93% +$59.5M
CGON icon
4
CG Oncology
CGON
$6.59B
$94.2M 2.79%
3,283,317
+112,442
+4% +$3.85M
GH icon
5
Guardant Health
GH
$21.7B
$87M 2.58%
2,847,931
-494,193
-15% -$13.9M
ALGN icon
6
Align Technology
ALGN
$11.2B
$78.2M 2.32%
375,179
+63,500
+20% +$14.2M
APGE icon
7
Apogee Therapeutics
APGE
$10.2B
$69.8M 2.07%
1,540,362
-102,864
-6% -$5.25M
KNSA icon
8
Kiniksa Pharmaceuticals
KNSA
$6.09B
$68.3M 2.02%
3,452,447
+557,934
+19% +$12.7M
APLS
9
DELISTED
Apellis Pharmaceuticals
APLS
$67M 1.99%
2,098,866
-1,026,317
-33% -$30.9M
IRTC icon
10
iRhythm Holdings
IRTC
$3.96B
$63.6M 1.89%
705,391
-77,166
-10% -$6.06M
EWTX icon
11
Edgewise Therapeutics
EWTX
$4.64B
$62.3M 1.85%
2,332,196
+373,886
+19% +$11.9M
DAWN
12
DELISTED
Day One Biopharmaceuticals
DAWN
$61.8M 1.83%
4,873,853
– –
SYRE icon
13
Spyre Therapeutics
SYRE
$7.97B
$60M 1.78%
2,578,404
+388,568
+18% +$11.4M
VKTX icon
14
Viking Therapeutics
VKTX
$3.75B
$59.5M 1.77%
1,479,666
+322,689
+28% +$18.4M
TMDX icon
15
Transmedics
TMDX
$3.07B
$57.5M 1.7%
+922,100
New +$85.8M
INSP icon
16
Inspire Medical Systems
INSP
$1.78B
$54.4M 1.61%
293,410
+54,499
+23% +$10.6M
ARGX icon
17
argenx
ARGX
$64B
$49.7M 1.47%
80,766
-15,958
-16% -$9.35M
TMO icon
18
Thermo Fisher Scientific
TMO
$230B
$46.7M 1.38%
+89,754
New +$49.3M
MRVI icon
19
Maravai LifeSciences
MRVI
$1.14B
$45.5M 1.35%
8,353,287
– –
SRPT icon
20
Sarepta Therapeutics
SRPT
$2.2B
$44.4M 1.32%
364,900
-5,500
-1% -$674K
PEN icon
21
Penumbra
PEN
$12.7B
$43.7M 1.29%
183,828
-177,600
-49% -$40.4M
GKOS icon
22
Glaukos
GKOS
$10.6B
$43.3M 1.28%
288,876
-22,740
-7% -$3.13M
AVDL
23
DELISTED
Avadel Pharmaceuticals
AVDL
$43.2M 1.28%
4,105,726
+716,787
+21% +$8.7M
RGEN icon
24
Repligen
RGEN
$9.95B
$40.9M 1.21%
283,823
-112,958
-28% -$16.2M
FNA
25
DELISTED
Paragon 28, Inc.
FNA
$39.6M 1.17%
3,834,809
-300,300
-7% -$2.42M
1
2 3 4

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q4 2024 Portfolio in Review

As of Q4 2024, Braidwell held 92 positions worth $3.37B, down 4.4% from $3.53B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Braidwell withdrew a net $860M in Q4 2024, closing 19 positions and reducing 14 holdings. Its most notable exit was Madrigal Pharmaceuticals, an estimated $39M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 66% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Braidwell opened a new position in Transmedics worth $57.5M.

  • Braidwell's largest Q4 2024 buy was Transmedics: 922,100 shares worth $57.5M.
  • Braidwell added most to Keros Therapeutics in Q4 2024, an estimated $61.7M increase.
  • Braidwell's biggest Q4 2024 reduction was Penumbra, cutting an estimated $40.4M.
  • Braidwell fully exited Madrigal Pharmaceuticals in Q4 2024, selling an estimated $39M.
  • Braidwell's ten largest holdings make up 37% of its $3.37B portfolio in Q4 2024.
  • Braidwell opened 13 new positions and closed 19 in Q4 2024.
  • Braidwell's portfolio value fell 4.4% quarter-over-quarter to $3.37B.

Based on Braidwell's 13F filing for Q4 2024, filed 14 Feb 2025.